Waters Corporation has announced that the Max Planck Institute is enhancing its research on neurodegenerative diseases by adding a Waters® Synapt High Definition MS™ (HDMS) System to its complement of research technologies.
The Institute's Department of Cellular Biochemistry recently took delivery of its Synapt™ HDMS System to study the role of proteins in causing brain-wasting diseases including Huntington's disease.
"Our initial impression of the Synapt HDMS system was of a very powerful two-dimensional separation device. We wanted a system that could measure large intact protein complexes with high accuracy. The ability to additionally separate species by ion mobility greatly enhances the appeal of this system," commented Prof. Ulrich Hartl, Director and Principal Investigator, Dr. Manajit Hayer-Hartl.
Dr. Hayer-Hartl's research focuses on the understanding of the mechanisms by which molecular chaperones mediate protein folding and inhibit misfolding in neurodegenerative diseases. The Synapt System will analyze the large protein complexes, and their subunit composition, that are involved in such diseases.
Prof. Hartl and Dr. Hayer-Hartl are looking to the Synapt System to give them greater insight into protein folding, assembly, and aggregation pathways by being able to resolve, identify and characterize intermediates based on differences in conformation.
"We will follow folding and/or aggregation pathways in the presence or absence of chaperone systems in combination with hydrogen/deuterium exchange technology," Dr. Hayer-Hartl explained.
"The Synapt System's Triwave technology for separating ions by their mobility will allow us to characterize our proteins of interest in greater detail than any other mass spectrometry system currently available," he continued.
Society of Mass Spectrometry annual meeting in Seattle in June of 2006.